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An optimal measurement of glomerular filtration rate (GFR)
should minimize the number of blood draws, and reduce
procedural invasiveness and the burden to study personnel
and cost, without sacrificing accuracy. Equations have been
proposed to calculate GFR from the slow compartment
separately for adults and children. To develop a universal
equation, we used 1347 GFR measurements from two diverse
groups consisting of 527 men in the Multicenter AIDS Cohort
Study and 514 children in the Chronic Kidney Disease in
Children cohort. Both studies used nearly identical two-
compartment (fast and slow) protocols to measure GFR. To
estimate the fast component from markers of body size and
of the slow component, we used standard linear regression
methods with the log-transformed fast area as the
dependent variable. The fast area could be accurately
estimated from body surface area by a simple parameter
(6.4/body surface area) with no residual dependence on the
slow area or other markers of body size. Our equation
measures only the slow iohexol plasma disappearance curve
with as few as two time points and was normalized to
1.73m2 body surface area. It is of the form: GFR¼ slowGFR/
[1þ 0.12(slowGFR/100)]. In a random sample utilizing a third
of the patients for validation, there was excellent agreement
between the calculated and measured GFR with low root
mean square errors being 4.6 and 1.5ml/min per 1.73m2 for
adults and children, respectively. Thus, our proposed simple
equation, developed in a combined patient group with a
broad range of GFRs, may be applied universally and is
independent of the injected amount of iohexol.
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Glomerular filtration rate (GFR) can be determined accu-
rately by measuring the plasma clearance of a single intra-
venous injection of a contrast medium such as iohexol,
calculated from plasma sampling at multiple time points over
several hours1,2 using an open two-compartment (slope–
intercept) mathematical model for the plasma disappearance
curve. The protocols to measure GFR in the Multicenter
AIDS Cohort Study (MACS) and Chronic Kidney Disease in
Children (CKiD) study involved four venous blood samples
after a single bolus injection of iohexol. To properly estimate
the two compartments, referred to hereafter as ‘fast’ for the
first compartment, and ‘slow’ for the second compartment,
two of the four blood samples were collected withinB30min
of the injection (for the fast compartment) and the other two
were obtained X2 h after the injection (for the slow
compartment). The ratio of the injected amount of iohexol
to the area under the disappearance curve is a direct measure
of GFR. This ‘gold-standard’ protocol is time intensive and
requires multiple blood draws, thereby increasing complexity
of large epidemiologic studies.2,3 An optimal GFR measure-
ment should minimize the number of blood draws,
procedural invasiveness, burden to study personnel, and cost.
Restricting sampling to only the slow compartment of the
model has been proposed in adults4,5 and children.2,6 GFR
equations to quantify a universal relationship between the
one-compartment (slow) and the two-compartment (slow þ
fast) plasma disappearance models have been published,
based on diverse, but small, study samples (combining adults
and children) representing different clinical populations
(that is, varying levels of renal function).7–9 Thus, the
purpose of the current study was to develop a formula to
determine the two-compartment GFR for studies where
samples in the fast compartment are not collected. To
accomplish this, we used iohexol-based studies that measured
both the slow disappearance curve and the fast disappearance
curve in two large-scale, clinically disparate populations.
Our analysis includes large populations with a broad range of
GFRs and thus should provide a strong basis for a universally
applicable equation.
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The protocol for measuring GFR in the MACS and CKiD
study used a two-compartment, four blood sample model of
plasma iohexol disappearance to calculate GFR (see Materials
and Methods). Two GFR values were calculated: one GFR
based on the slow compartment only (GFR0,2) and the other
GFR based on both the fast and slow compartments (GFR2,2;
see Variables subsection). As there is a close relationship
between GFR0,2 and GFR2,2, two approaches have been
proposed to estimate GFR2,2 from GFR0,2; this estimate
is denoted hereafter as dGFR2;2. These approaches are: (1) the
classical Brochner-Mortensen equation4 that has been used
typically in clinical guidelines5 and epidemiological research;2
and (2) a new equation based on theoretical underpinnings
by Fleming7 and Brochner-Mortensen and Jodal.8,9
In this study, we aimed to develop a formula to estimate
the fast component in GFR2,2 not measured in GFR0,2 (that
is, missing fast area). Once such a formula was developed, we
derived the corresponding formula to determine GFR2,2
based on GFR0,2, and we position our proposed equation in
the context of the recently improved principles.7–9 The MACS
and CKiD studies provided an excellent opportunity to
develop a universal equation because the GFR-measuring
protocols were nearly identical (except for the time of the last
blood sample: 240min in the MACS and 300min in CKiD)
and included the same central biochemistry laboratory
(principal investigator GJS, University of Rochester Medical
Center, Rochester, NY) and the same data coordinating
center (co-principal investigators AM and LPJ, Johns
Hopkins Bloomberg School of Public Health, Baltimore,
MD), although the two populations studied were extremely
different. Agreement between dGFR2;2 and GFR2,2 within each
study population, therefore, would assess the appropriateness
of a truly universal equation. Such a robust equation would
highlight any common dynamics between these two disparate
groups and permit future iohexol GFR studies in any
population to accurately determine GFR using only two
plasma samples.
RESULTS
Table 1 presents descriptive statistics of the 527 adult men
from the MACS and the 514 children from the CKiD cohort
who were studied. In the CKiD data set, 63% of subjects
underwent one GFR2,2 study, 36% had two studies, and
1% had three studies (with repeated studies at B1-year
intervals), yielding a total of 820 GFR2,2 studies. The two
cohorts differed substantially in most characteristics shown
in Table 1. The MACS subjects were adult men with a median
age of 51 years, and the CKiD subjects were children
(62% male) with a median age of 11 years. Human
immunodeficiency virus (HIV) infection was an exclusion
criterion for CKiD, but 70% of the MACS subjects were HIV
infected. In CKiD, a cohort of children with chronic kidney
disease, 21% had glomerular kidney disease.
Table 2 presents the plasma disappearance parameters by
study cohort and by training data set (for model develop-
ment using a 2/3 random sample) and validation data set
(for evaluation of agreement between observed and estimated
GFR using the remaining 1/3 random sample). All para-
meters were significantly different between the cohorts except
for the injected iohexol, which was B3200mg by the
common protocol. As expected, randomization yielded
Table 1 | Descriptive statistics (percent or median (interquartile
range)) of clinical and demographic characteristics of the
MACS and CKiD populations at baseline
Characteristic MACS (n=527) CKiD (n=514)
Age (years) 50.9 (46.0, 57.1) 11.1 (7.7, 14.7)
Male 100% 62%
Race
White 57% 66%
Black 35% 23%
Other 8% 12%
Height (m) 1.76 (1.71, 1.80) 1.40 (1.20, 1.58)
Weight (kg) 80.7 (72.6, 90.4) 36.3 (23.7, 54.8)
BMI (kg/m2) 26.2 (23.9, 28.8) 18.3 (16.2, 22.0)
BSA (m2) 2.00 (1.87, 2.14) 1.19 (0.89, 1.57)
HIV infected 70% 0%
Serum creatinine (mg/dl) 0.92 (0.79, 1.08) 1.30 (1.00, 1.80)
GFR2,2 (ml/min per 1.73m
2) 109.2 (94.9, 125.2) 44.0 (32.8, 56.0)
Abbreviations: BMI, body mass index; BSA, body surface area; CKiD, Chronic Kidney
Disease in Children Cohort Study; GFR, glomerular filtration rate; HIV, human
immunodeficiency virus; MACS, Multicenter AIDS Cohort Study.
Table 2 |Median (interquartile range) of plasma disappearance parameters of iohexol studies for the training and validation
data sets from the MACS and CKiD populations
Training data set (2/3 random sample) Validation data set (1/3 random sample)
MACS (n=350) CKiD (n=546) P-valuea MACS (n=177) CKiD (n=274)
Iohexol injection (mg) 3180 (3151, 3243) 3190 (3156, 3223) 0.426 3185 (3127, 3223) 3192 (3160, 3228)
Fast areab (mg min/ml) 3.2 (2.6, 3.9) 5.7 (4.0, 8.1) o0.001 3.4 (2.8, 4.1) 5.3 (3.7, 8.2)
Slow areac (mg min/ml) 21.9 (18.6, 25.5) 107.6 (73.9, 156.2) o0.001 21.3 (18.7, 25.0) 97.5 (63.8, 142.8)
GFR0,2
d (ml/min per 1.73m2) 125.3 (105.5, 149.0) 45.3 (33.4, 59.2) o0.001 128.3 (110.0, 150.1) 47.7 (36.2, 63.6)
GFR2,2
e (ml/min per 1.73m2) 108.6 (93.8, 126.2) 42.9 (32.0, 54.8) o0.001 112.1 (96.3, 124.9) 45.4 (34.6, 58.6)
Abbreviations: CKiD, Chronic Kidney Disease in Children Cohort Study; GFR, glomerular filtration rate; MACS, Multicenter Aids Cohort Study.
aWilcoxon rank-sum test comparing MACS and CKiD in training data set; bold indicates statistically significant (Po0.05).
bBased on plasma samples at 10 and 30min after iohexol injection.
cBased on plasma samples at 120 and 240min for MACS and 120 and 300min for CKiD after iohexol injection.
d(Iohexol injection/slow area) (1.73/BSA).
e(Iohexol injection/total area) (1.73/BSA).
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similar parameters for the training and validation data sets
for each cohort. For CKiD, these parameters indicated renal
insufficiency. In contrast, most of the MACS had normal
renal function: 81% of these subjects had a GFR2,2 X90ml/
min per 1.73m2.
Predictors of the fast area
The left side of Table 3 shows the regression coefficients and
R2 for the univariate regressions with the dependent variable
being the fast area in the log scale. All variables showed
substantial associations with the fast area. In particular, the
fast area was inversely proportional to body surface area
(BSA; that is, coefficient of BSA was close to, and not
statistically different from, –1). Furthermore, there was a
strong positive relationship between the slow and fast areas,
with the slow area explaining close to 34% of the variability
in fast area. Given the strong relationship between the fast
area and BSA, we explored the predictive power of variables
in Table 3 on the variability of the fast area unexplained by
BSA. The right side of Table 3 shows that none of the
predictors explain the variability of residuals of the regression
of fast area on BSA. In particular, the strong univariate
association between slow and fast area completely disap-
peared when the dependent variable was BSA-adjusted
fast area (regression coefficient¼0.018 (P¼ 0.194), R2¼
0.2%). Further evidence of the lack of association between
the fast and slow area conditional on BSA is the fact that the
R2¼ 34% observed in the overall univariate relationship
between the fast and slow area reduced to 0.6, 0.1, 0.7, and
1.6% in four strata defined by quartiles of BSA.
Figure 1a shows that the relationship between fast area and
BSA (R2¼ 56%) is given by fast area¼ 6.46 (BSA)1.023.
More importantly, Figure 1b shows that once the variability
of fast area due to BSA has been accounted for, there is no
additional information from the slow area (R2¼ 0.2%).
Hence, the fast area depends on BSA, but not on the slow
area once BSA has been taken into account.
Formula to determine GFR2,2 from GFR0,2
Not only does the fast area not depend on the slow area once
BSA has been taken into account, but the relationship
between the fast area and BSA can be simplified to
fast area ¼ 6:4/BSA
and we can derive an equation to determine GFR2,2 in terms
of GFR0,2. Specifically, by simply dividing both sides of the
above equation by the slow area and multiplying and
dividing the right-hand side of the equation by 1.73 I
(where I is the injected amount of iohexol), the equation
becomes
fast area=slow area ¼ ð6:4=ð1:73IÞÞGFR0;2:
As by protocol, I is close to 3200 and has very low variability
(see Table 2), 6.4/(1.73 I) is equal to 0.00116 (which
hereafter we round to 0.0012). In addition, the ratio of fast to
slow area is simply (GFR0,2/GFR2,2) – 1.
Table 3 | Univariate linear regression models used to
determine the percent of explained variance of
BSA-unadjusted and BSA-adjusted fast area for the
combined MACS (n=350) and CKiD (n=546) training data set
Dependent variable
BSA-unadjusted
fast areab
BSA-adjusted
fast areac
Independent variablea
Regression
coefficient R2
Regression
coefficient R2
BSA (m2) 1.023 55.9% — —
Slow area (mg min/ml) 0.359 33.6% 0.018 0.2%
GFR0,2 (ml/min per 1.73m
2) 0.315 12.2% 0.041 0.5%
Height (m) 2.075 56.4% 0.082 0.2%
Weight (kg) 0.670 54.6% 0.006 o0.1%
BMI (kg/m2) 1.187 32.2% 0.128 0.8%
Age (years) 0.430 49.9% 0.022 0.3%
Male gender 0.335 6.6% 0.032 0.1%
Abbreviations: BMI, body mass index; BSA, body surface area; CKiD, Chronic Kidney
Disease in Children Cohort Study; GFR, glomerular filtration rate; MACS, Multicenter
AIDS Cohort Study.
aAll variables except gender in natural logarithmic scale.
bDependent variable is the natural log of the observed fast area.
cDependent variable is the residual of the regression of fast area on BSA (log scale).
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Figure 1 |Relationships between fast area, BSA, and slow
area. (a) Regression of fast area (y axis) on body surface area
(BSA; x axis) in the log scale for the combined Multicenter AIDS
Cohort Study (MACS) and Chronic Kidney Disease in Children
(CKiD) training data set. The dashed line represents the
nonparametric spline. (b) Non-relationship of residuals from the
regression of fast area on body surface area presented in a (y axis)
and slow area (x axis) from the training data set.
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Hence,
ðGFR0;2=GFR2;2Þ  1 ¼ 0:0012GFR0;2
which, solving for GFR2,2, yields our proposed equation for
dGFR2;2 from GFR0,2 as follows:
dGFR2;2 ¼ GFR0;2=½1þ 0:12ðGFR0;2=100Þ
or, in short,
dGFR ¼ slowGFR=½1þ 0:12ðslowGFR=100Þ
This equation is of the same form as the one proposed by
Fleming7 and simpler than the one proposed by Brochner-
Mortensen and Jodal.9 More importantly, the form of the
equation is consonant with the theoretical and physiological
considerations put forward by these authors.
Figure 2 plots the data for (GFR0,2/GFR2,2) – 1 (y axis) on
GFR0,2 (x axis) and it indicates that the equation including
the simple proportionality factor of 0.12 not only fits the data
well for both cohorts but also explains 75% of the variability
for the combined training data set.
Evaluation of equations to calculate dGFR2;2 and agreement
between dGFR2;2 and GFR2,2
For the validation data sets of each study population (1/3
random sample), Table 4a and b describes the agreement of
GFR2,2 (measured) and the dGFR2;2 (estimated) from four
different GFR0,2-based equations. The equations evaluated
included the original Brochner-Mortensen equations for
adult4 and pediatric6 populations; those published by
Brochner-Mortensen and Jodal8 and Fleming;7 and our
proposed equation.
The original Brochner-Mortensen equations showed
significant underestimation of GFR2,2 in the MACS (bias:
3.3%, 95% confidence interval (CI): 3.9, 2.7%) and in
the CKiD (1.7%, 95% CI: 2.0%, 1.4%). The equations
also produced significant underdispersion in both popula-
tions and higher root mean square errors (RMSEs) and lower
percentages of dGFR2;2 within 5% of GFR2,2 than those of our
proposed equation. Although these estimates were statisti-
cally significant, the effect size was relatively small. The
equations proposed by Brochner-Mortensen and Jodal9 and
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Figure 2 |Relationship between GFR0,2 (x axis) and (GFR0,2/
GFR2,2) – 1 (y axis) in the log scale, for the combined
Multicenter AIDS Cohort Study (MACS) and Chronic Kidney
Disease in Children (CKiD) training data set. The equation,
(GFR0,2/GFR2,2) – 1¼ 0.12 (GFR0,2/100), is depicted as the solid
line. GFR, glomerular filtration rate.
Table 4 | Agreement of the estimated GFR (dGFR2;2) based on two-point GFR from the slow curve only (GFR0,2) and selected
models with the observed four-point GFR (GFR2,2) in the (a) MACS (n=177) and (b) CKiD (n=274) validation data sets
Model of dGFR2;2 as a function of GFR0,2 and BSA Source
Bias ratio
(95% CI)
Ratio of s.d.’s
(95% CI)
Correlation
(95% CI) RMSE
% of dGFR2;2
within 5% of
GFR2,2
(a) MACS validation data set (n=177)
Original Brochner-Mortensen
C1 (GFR0,2/100) + C2 (GFR0,2/100)
2
C1=98.31; C2=–0.1218
Brochner-Mortensen4 0.967
(0.961, 0.973)
0.937
(0.909, 0.965)
0.978
(0.971, 0.984)
6.49 62.7%
GFR0,2/[1+ B0  (GFR0,2/100)B1  BSAB2]
B0=0.185; B1=1, B2=–0.3
Brochner-Mortensen
and Jodal8,9
0.972
(0.967, 0.978)
0.960
(0.934, 0.986)
0.979
(0.972, 0.984)
5.80 66.1%
GFR0,2/[1+B0  (GFR0,2/100)B1]
B0=0.17; B1=1
Fleming7 0.953
(0.947, 0.959)
0.941
(0.916, 0.967)
0.979
(0.972, 0.984)
7.49 49.7%
MACS and CKiD proposed equation
GFR0,2/[1+B0  (GFR0,2/100)B1]
B0=0.12; B1=1
Training set
CKiD + MACS 2/3
random sample (n=896)
1.005
(1.000, 1.011)
0.987
(0.962, 1.013)
0.980
(0.972, 0.985)
4.59 79.1%
(b) CKiD validation data set (n=274)
Original Brochner-Mortensen
C1 (GFR0,2/100) + C2 (GFR0,2/100)
2
C1=101.0; C2=–0.17
Brochner-Mortensen et al.6 0.983
(0.980, 0.986)
0.968
(0.959, 0.976)
0.996
(0.995, 0.997)
2.04 91.2%
GFR0,2/[1+ B0  (GFR0,2/100)B1  BSAB2]
B0=0.185; B1=1, B2=–0.3
Brochner-Mortensen
and Jodal8,9
0.978
(0.975, 0.981)
0.984
(0.976, 0.992)
0.996
(0.995, 0.997)
1.92 86.5%
GFR0,2/[1+B0  (GFR0,2/100)B1]
B0=0.17; B1=1
Fleming7 0.980
(0.978, 0.983)
0.983
(0.974, 0.991)
0.996
(0.995, 0.997)
1.87 90.9%
MACS and CKiD proposed equation
GFR0,2/[1+B0  (GFR0,2/100)B1]
B0=0.12; B1=1
Training set
CKiD + MACS 2/3
random sample (n=896)
1.004
(1.001, 1.006)
1.005
(0.996, 1.013)
0.996
(0.995, 0.997)
1.46 96.0%
Abbreviations: BSA, body surface area; CI, confidence interval; CKiD, Chronic Kidney Disease in Children Cohort Study; GFR, glomerular filtration rate; MACS, Multicenter AIDS
Cohort Study; RMSE, root mean square error.
Bold indicates statistically significantly different from 1 (that is, Po0.05).
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Fleming7 each yielded a slight systematic underestimation
and underdispersion in both populations. Our proposed
equation, based upon the MACS and CKiD, showed good
agreement in each validation data set. In the MACS data set,
there was no significant bias or difference in dispersion
associated with dGFR2;2 compared with GFR2,2. In the CKiD
data set, there was a minor, but significant, overestimation
(bias: þ 0.4%, 95% CI: 0.1%, 0.6%) and no significant
overdispersion (ratio of s.d.’s: þ 0.5%, 95% CI: 0.2%,
1.3%), but these effects were small (p1%). The proposed
equation also provided the lowest RMSE and the highest
percentage of dGFR2;2 being within 5% of GFR2,2 of the
equations tested. The correlations between all four equations
were high and essentially the same in both the MACS
(r¼ 0.980) and CKiD (r¼ 0.996) validation data sets.
Figure 3 depicts agreement of dGFR2;2 calculated using the
MACS and CKiD proposed equation with GFR2,2. The dGFR2;2
values were essentially identical to GFR2,2 with minimal
bias, a preservation of dispersion, low RMSE, and very high
correlation in these two distinct populations.
DISCUSSION
Current guidelines provide separate equations to calculate
dGFR2;2 for adults and children, but the present analysis
shows that a universal equation is applicable in diverse
populations. The literature often cautions that equations to
calculate dGFR2;2 are appropriate only in populations similar
to those in which they were developed. In the present study,
two large studies of different populations, demographically
diverse and with a broad range of renal function, underwent
essentially the same iohexol GFR2,2 measurement protocols;
this allowed us to develop an equation suitable for both
populations. Crucial findings for the proposed universal
equation were that the fast area was inversely proportional
to BSA and that the BSA-adjusted fast area was independent
of the slow area. Thus, BSA was a key consideration when
evaluating the common dynamic between these two popula-
tions, and must routinely be accounted for when measuring
GFR.
The simple relationship between the fast area and BSA
allowed the derivation of a simple equation to calculate
dGFR2;2 from GFR0,2, as measured by an iohexol-based GFR
protocol. To confirm this derivation, a direct regression
analysis was performed on the data in Figure 2. Indeed,
the slope (¼ 1.025) was not significantly different from 1
(95% CI: 0.987, 1.063), and the intercept (that is, at
GFR0,2¼ 100ml/min per 1.73m2) was equal to 0.117.
Our proposed equation provides an accurate and reliable
GFR measurement from as few as two blood samples
collected between 120 and 300min after injection of iohexol.
This modification of the iohexol-based protocol represents
an important reduction in study burden for subjects and
personnel, and should facilitate GFR measurements in
large-scale clinical and epidemiological studies.
Our analysis assessed the agreement between GFR2,2 and
dGFR2;2 of our proposed equation as well as of previously
published equations.4,7–9 Although the previously published
equations showed good agreement, our proposed equation
was even better: RMSEs were 4.59 and 1.46ml/min
per 1.73m2 for the MACS and CKiD validation data sets,
respectively. Furthermore, our proposed equation had
the highest proportion of dGFR2;2 within 5% of the GFR2,2
(79% for MACS and 96% of CKiD).
Importantly, the equation dGFR2;2¼ GFR0,2/[1þ 0.12
(GFR0,2/100)] is consistent in form with the equations
proposed by Brochner-Mortensen and Jodal8,9 and Fleming7
and coheres with the theoretical principles discussed by these
authors. Specifically, using the general expression:
GFR0;2=ð1þ B0 GFR0;2=100ÞB1BSAB2Þ
the Brochner-Mortensen and Jodal8,9 equation corresponds
to B0¼ 0.185, B1¼ 1, and B2¼ –0.3; the Fleming7 equation
corresponds to B0¼ 0.17, B1¼ 1, and B2¼ 0; and our
proposed equation corresponds to B0¼ 0.12, B1¼ 1, and
B2¼ 0.
Another feature of our proposed equation is that it is
invariant with respect to the injected amount of iohexol.
Indeed, the relationship describing GFR0,2 and the ratio of
GFR0,2 to GFR2,2 in Figure 2 is not dependent on the dose of
iohexol and the equation with 0.12 provided an excellent fit
to the data. In contrast, the constant of 6.4 relating fast
area to BSA is directly proportional to the dose of iohexol
and in general, if fast area¼ c/BSA, c will be equal to
0.00116 1.73 I, where c¼ 6.4 for I¼ 3200. Thus, our
proposed equation may be applicable to other iohexol
protocols (with variations in amounts of iohexol injection),
although the estimation of fast area by 6.4/BSA is specific to
this protocol (that is, when I¼ 3200mg).
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Figure 3 |Comparison ofdGFR2;2 based on GFR0,2 and proposed
equation with four-point GFR2,2 in the validation data sets for
Multicenter AIDS Cohort Study (MACS; n¼ 177) and Chronic
Kidney Disease in Children (CKiD; n¼ 274). Percentile (2.5th,
5th, 10th, 25th, 50th, 75th, 90th, 95th, and 97.5th) box plots
showing a high agreement within each study validation data set.
GFR, glomerular filtration rate; RMSE, root mean square error.
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The difference between the Fleming equation and our
equation was meaningful: the Fleming equation had relatively
high RMSE in our study populations and it systematically
underestimated GFR2,2, although this underestimation
was modest (B2% in the CKiD and 5% in the MACS). This
slight discrepancy may be because of differences in the
exogenous clearance markers used (that is, iohexol versus
51Cr-EDTA); however, previous studies have shown compar-
able GFR measurement performance with either marker.10–12
It is also possible that this discrepancy may be because of
other factors altogether (that is, study design or model
development).
The relationship between fast area and BSA determined in
Table 3 and depicted in Figure 1a (R2¼ 56%) may be re-
expressed to form the basis of our proposed equation whose fit
to the data is depicted in Figure 2 (R2¼ 75%). Given that the
fast area depends solely on BSA, we compared our proposed
equation with the agreement in an equation that directly
imputes the fast area as inversely proportional to BSA:
dGFR2;2 ¼ ½I=ðð6:4=BSAÞ þ slow areaÞ1:73=BSA
This equation yielded RMSEs of 5.81 and 1.48ml/min per
1.73m2 in the MACS and CKiD, respectively; which, for the
MACS, was 27% higher than the RMSE of 4.59 of our
proposed equation (dGFR2;2 as a function of GFR0,2). As the
main assumption from the analysis is that the fast area depends
only on BSA, the proposed equation does not take into account
the between-subject variability in the fast area among those
with the same BSA. Despite this limitation, the assumption
works well because the fast area does not contribute much to
the overall GFR2,2.
As a secondary analysis, we also investigated how a
previously published Brochner-Mortensen-like equation that
was developed exclusively in the CKiD population2 per-
formed when applied separately to the validation data sets in
the two studies. In the CKiD validation data set, there was no
significant bias or difference in dispersion, and a very high
correlation (r¼ 0.998, 95% CI: 0.995, 0.997) between dGFR2;2
and GFR2,2. This was expected as the equation was derived in
the same clinical population. However, when the equation
was applied to the MACS validation data set, the measures of
agreement were much poorer: there was significant under-
estimation (bias¼2.6%, Po0.01), shrinking of dispersion
(ratio of s.d.’s¼ 0.932, Po0.01), and lower correlation
(r¼ 0.978, 95% CI: 0.971, 0.984) than had been observed
in the CKiD validation data set. This finding highlights a
limitation of developing an equation within a specific
population and then applying it to a different one. As such,
a limitation of our study is the lack of adult female subjects
studied, with whose data we could have assessed the validity
of the proposed equation. Nevertheless, ours is the only study
that has developed an accurate iohexol dGFR2;2 equation using
two disparate, large-scale cohorts (total n¼ 1347) that
underwent essentially identical GFR protocols.
Although the fast area can be estimated from the body
surface area, it should be noted that the intercept and slope of
the fast curve cannot be determined with our method.
Determination of these parameters (needed for measures like
the extracellular volume13) would require collecting samples
within 60min of iohexol injection. Another limitation to our
method is that our data did not take into account obese or
edematous subjects, populations for which it is unclear
whether our approach will work. However, in spite of the
substantial differences in weight and body mass index
between the two study populations (that is, MACS men with
a median body mass index of 26 kg/m2 versus CKiD children
being overweight relative to their height), the analysis showed
excellent agreement in each population.
In conclusion, because of the fast area being dependent on
BSA but not on the slow area, determination of GFR using
only the slow component showed a remarkable consistency
between the MACS and CKiD populations. A simple
equation was derived from a training data set that included
both cohorts and showed excellent agreement when applied
to validation sets from both studies. Using this validated
equation, GFR can be accurately measured across popula-
tions with diverse demographics and renal function using
only the slow iohexol plasma disappearance curve with as few
as two time points.
MATERIALS AND METHODS
Variables
GFRx,y denotes the glomerular filtration rate calculated from
disappearance curves of iohexol-based studies. The subscript x,y
refers to the number of time points sampled in the first (fast) and
second (slow) compartments, respectively. Specifically, GFR2,2
denotes the GFR derived from sampling times of 10 and 30min
(that is, two time points in the fast compartment), and 120 and
240min (or 300min; that is, two time points in the slow
compartment) after iohexol injection; and GFR0,2 denotes the GFR
based only on the slow compartment. The area under the curve of
the second compartment is derived from the plasma iohexol
concentrations at 120 and 240min for the MACS and 120 and
300min for the CKiD, and is referred to as the slow area. Likewise,
based on concentrations at 10 and 30min after injection, we derived
the disappearance curve of the first compartment, whose area under
the curve is hereafter referred as the fast area. GFR2,2 was calculated
as the ratio of the amount of iohexol injected (I) to the total area
under the iohexol disappearance curve and calibrated to a BSA of
1.73m2. That is, GFR2,2¼ (I/(fast areaþ slow area)) (1.73/BSA).
If the fast area in the above expression is omitted, it yields GFR0,2¼
(I/slow area) (1.73/BSA), which always overestimates GFR2,2.
dGFR2;2 (with circumflex) denotes the estimate of GFR2,2 from an
equation based on GFR0,2 in studies where the two time points in
the fast compartment are not taken into account. A central aim of
this study was to determine the agreement between dGFR2;2 and
GFR2,2.
Study participants
The MACS is a prospective observational cohort study of the natural
and treated histories of HIV infection among homosexual/bisexual
men over the age of 18 in four sites in the United States. To
investigate the natural history of renal function as it relates
to HIV infection and use of highly active antiretroviral therapy, a
428 Kidney International (2011) 80, 423–430
t echn i ca l no tes DKS Ng et al.: Two-sample iohexol GFR for diverse populations
subgroup of the cohort (n¼ 565) participated in an iohexol-based
GFR measurement between August 2008 and May 2010. Of
these, 527 (94%) had a successful GFR2,2 study; we excluded
individual patient studies if there were problems with any plasma
concentration measurements (n¼ 32), if an incorrect amount
of iohexol was administered (n¼ 3), or if the study indicated an
extremely high GFR2,2 (that is, GFR2,2 4180ml/min per 1.73m
2;
n¼ 3).
The CKiD study enrolled 586 children between 1 and 16 years of
age with mild to moderate chronic kidney disease in 47 sites in
the United States and Canada. Enrollment criteria included an
estimated GFR range of 30 to 90ml/min per 1.73m2, based on the
original Schwartz formula.14 From these subjects, there were 915
subject visits at which an iohexol injection for a GFR2,2 protocol
occurred. For our analysis, 514 subjects (88% of 586) contributed a
total of 820 GFR2,2 studies (90%); we excluded studies if there
were problems with plasma concentration measurements or
blood sampling time values for any of the four samples (n¼ 38),
the wrong amount of iohexol was administered (o2000 or
44500mg; n¼ 5), if the GFR2,2 was significantly different
(450%) from the corresponding estimated GFR15 (n¼ 45), or if
the BSA calculation was based on only one measurement of height
and weight instead of the average of three measurements (n¼ 7).
BSA for both populations was calculated from the Haycock et al.16
formula.
The two studies used nearly identical iohexol GFR protocols: the
only difference was that the last blood sample after injection of iohexol
was collected at 240min in the MACS and at 300min in the CKiD.
This difference in the protocol was justified by the expectation of
relatively normal kidney function among the MACS men.
Both the MACS and CKiD studies were approved by Research
Review Boards at all participating sites in the United States and
Canada.
Statistical analysis
To overcome the limitation of studies that do not measure
concentrations of iohexol at time points in the fast compartment,
formulas to predict the fast area are needed. We used standard
linear regression methods with the log of the fast area as the
dependent variable and we examined the predictive power of the
following independent variables: BSA, slow area, GFR0,2, height,
weight, body mass index, age, and male gender. The prediction
formulas can be used to directly impute the missing fast area and
also to derive formulas to estimate GFR2,2 as a function of GFR0,2,
as this is the form that numerous investigators have previously
used.7–9 In order to develop a formula to predict the fast area, we
randomly selected a 2/3 sample of each cohort and combined these
two subgroups into a training data set in which the models were
developed. Once the predicted formula for the fast area was
developed, and in order to independently test the agreement
between GFR2,2 and dGFR2;2 we applied the equation for dGFR2;2
to the remaining 1/3 random sample from each study (validation
data set).
In all regression analyses, a generalized estimating equation was
used to account for correlation between repeated measurements and
to obtain correct standard errors.17 Results were unchanged when
we performed the same analysis using only the first GFR2,2 study
contributed by each CKiD subject (n¼ 514; training data set
n¼ 343, validation data set n¼ 171). To maximize the use of all
available GFR studies, the results from the generalized estimating
equation analyses using all the studies are reported.
Agreement between dGFR2;2 and GFR2,2
Agreement was assessed in the validation data set using methods
described by Bland and Altman18 and extended by regressing the
difference on the average of the two measurements centered around
the overall mean.1 Absence of bias corresponds to the intercept of
the regression being equal to zero and equal dispersion corresponds
to the slope being equal to zero.1 Robust methods were used to
account for repeated measurements. The 95% CIs for correlations
were determined by Fisher’s method. Agreement plots were used to
visually depict each data point and the box-percentile plots for
dGFR2;2 and GFR2,2 in each cohort.
19 To compare with other
published equations, in each MACS and CKiD data set, dGFR2;2 was
calculated from the published population-specific Brochner-Mor-
tensen-equations,4,6 the equations by Brochner-Mortensen and
Jodal9 and Fleming,7 and our proposed equation derived from the
training data set. The calculated dGFR2;2 values based on these four
equations were then compared with the observed GFR2,2 based on
both fast and slow compartments in the validation data set.
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